Article information
Resumen
La utilización de los tratamientos biológicos en el campo de la Dermatología ha sido reciente y se ha centrado prioritariamente en el tratamiento de la psoriasis. Etanercept ha demostrado su eficacia y seguridad en este campo, si bien es cierto que, por su mecanismo de acción y por su perfil de seguridad, se ha utilizado en numerosas patologías diferentes a la psoriasis con resultados variables. Presentamos un caso de acrodermatitis de Hallopeau tratada con etanercept con buenos resultados. Dadas las características de cronicidad, progresividad y en general mala respuesta a los tratamientos convencionales, el empleo de etanercept supone una ayuda en las posibilidades terapéuticas de la acrodermatitis de Hallopeau.
Se revisan además otras posibles indicaciones de etanercept en procesos diferentes a la psoriasis.
Palabras clave:
Etanercept
Psoriasis pustulosa
Tratamientos off-label
Abstract
The use of biological treatments in the field of Dermatology has been recent and priority focus has been given to the treatment of psoriasis. Etanercept has demonstrated its efficacy and safety in this field although it is true that it has been used in many different diseases other than psoriasis with variable results due to its action mechanism and safety profile. We present a case of Hallopeau's Acrodermatitis treated with etanercept with good results. Given the characteristics of chronicity, progressiveness and, in general, poor response to conventional treatments, the use of etanercept is of help in the therapeutic possibilities of Hallopeau's Acrodermatitis.
In addition, other possible indications of etanercept in conditions other than Psoriasis are reviewed.
Keywords:
Etanercept
Psoriasis pustulosa
Treatments off-label
Full text is only aviable in PDF
Bibliografía
[1.]
K. Kazinski, K.M. Joyce, D. Hodson.
The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of Hallopeau.
J Drugs Dermatol, 4 (2005), pp. 360-364
[2.]
E. Weisshaar, T.L. Diepgen.
Successful etanercept therapy in therapy refractory acrodermatitis continua suppurativa Hallopeau.
J Dtsch Dermatol Ges, 5 (2007), pp. 489-492
[3.]
K. Ahmad, S. Rogers.
Two years of experience with etanercept in recalcitrant psoriasis.
Br J Dermatol, 156 (2007), pp. 1010-1014
[4.]
B. Bonish, R.M. Rashid, J. Swan.
Etanercept responsive acrodermatitis continua of Hallopeau: is a pattern developing?.
J Drugs Dermatol, 5 (2006), pp. 903-904
[5.]
J. LaDuca, A.A. Gaspari.
Targeting tumour necrosis factor alpha. New drugs used to modulate inflammatory diseases.
Dermatol Clin, 19 (2001), pp. 617-635
[6.]
S. Nanda, J.M. Bathon.
Etanercept a clinical review of current and emerging indications.
Expert Opin Pharmacother, 5 (2004), pp. 1175-1186
[7.]
J.E. Graves, K. Nunley, M.P. Heffernan.
Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2).
J Am Acad Dermatol, 56 (2007), pp. e55-e79
[8.]
M.G. Lebwohl.
Use of etanercept in the dermatology setting. A review.
Am J Clin Dermatol, 6 (2005), pp. 49-59
[9.]
G. Guhl, B. Díaz-Ley, J. Fernández-Herrera.
Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab.
Actas Dermosifiliogr, 99 (2008), pp. 5-33
[10.]
M. Aringer, J.S. Smolen.
Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention.
Lupus, 13 (2004), pp. 344-347
[11.]
E.P. Sampaio, E.N. Sarno, R. Galilly, Z.A. Cohn, G. Kaplan.
Thalidomide selectivity inhibits tumor necrosis factor alpha production by stimulated human monocytes.
J Exp Med, 173 (1991), pp. 699-703
[12.]
M. Ramos-Casals, P. Brito-Zerón, S. Muñoz, M-J. Soto, BIOGEAS Study Group.
A systematic review of the off-label use of biological therapies in systemic autoimmune diseases.
Medicine, 87 (2008), pp. 345-364
[13.]
M. Hasegawa, M. Fujimoto, K. Kikuchi, K. Takehara.
Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis.
J Rheumatol, 24 (1997), pp. 663-665
[14.]
M.H. Ellman, P.A. MacDonald, F.A. Hayes.
Etanercept as a treatment for diffuse scleroderma: a pilot study.
Arthritis Rheum, 43 (2000), pp. s392
[15.]
M. Hasegawa, S. Sato, T. Nagaoka, M. Fujimoto, K. Takehara.
Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma.
Dermatology, 207 (2003), pp. 141-147
[16.]
J.G. Krueger.
The immunologic basis for the treatment of psoriasis with new biologic agents.
J Am Acad Dermatol, 46 (2002), pp. 1-23
[17.]
H. Iizuka, H. Takahashi, A. Ishida-Yamamoto.
Pathophysiology of generalized pustular psoriasis.
Arch Dermatol Res, 295 (2003), pp. S55-S59
[18.]
M.A. Reuss-Borts, G. Pawelec, J.G. Saal, H.P. Horny, C.A. Muller, H.D. Waller.
Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease.
Br J Haematol, 84 (1993), pp. 356-358
[19.]
J.J. Grob, J.L. Mege, C. Capo, E. Jancovicci, J.R. Fournerie, P. Bongrand, et al.
Role of tumor necrosis factor- in Sneddon-Wilkinson subcorneal pustular dermatosis. A model of neutrophil priming in vivo.
J Am Acad Dermatol, 25 (1991), pp. 944-947
[20.]
G. Goldenberg, J.L. Jorizzo.
Use of etanercept in treatment of pyoderma gangrenosum in a patien with autoimmune hepatitis.
J Dermatolog Treat, 16 (2005), pp. 347-349
[21.]
J.W. Mc-Gowan 4th, C.A. Johnson, A. Lynn.
Treatment of pyoderma gangrenosum with etanercept.
J Drugs Dermatol, 3 (2004), pp. 441-444
[22.]
N. Pastor, I. Betlloch, J.C. Pascual, M. Blanes, J. Banuls, J.F. Silvestre.
Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept).
Clin Exp Dermatol, 31 (2006), pp. 152-153
[23.]
P.S. Yamauchi, L. Turner, N.J. Lowe, V. Gindi, J.M. Jackson.
Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept.
J Am Acad Dermatol, 54 (2006), pp. S122-S126
[24.]
R.W. Groves, M.H. Allen, E.L. Ross, J.N. Barker, D.M. MacDonald.
Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression.
Br J Dermatol, 132 (1995), pp. 345-352
[25.]
K. Nakamura, A. Saitoh, N. Yasaka, M. Furue, K. Tamaki.
Molecular mechanisms involved in the migration of epidermal dentritic cells in the skin.
J Invest Dermatol Symp Proc, 4 (1999), pp. 169-172
[26.]
L. D’Auria, P. Cordiali Fei, F. Ameglio.
Cytokines and bullous pemphigoid.
Eur Cytokine Net, 10 (1999), pp. 123-134
[27.]
F. Ameglio, L. D’Auria, C. Bonifati, C. Ferraro, A. Mastroianni, B. Giacalone.
Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity.
Br J Dermatol, 138 (1998), pp. 611-614
[28.]
L.E. Rhodes, I.A. Hashim, P.J. MaLaughlin, P.S. Friedmann.
Blister fluid cytokines in cutaneous inflammatory bullous disorders.
Acta Derm Venereol, 79 (1999), pp. 288-290
[29.]
C. Sacher, A. Rubbert, C. Konig, K. Scharffetter-Kochanek, T. Krieg, N. Hunzelmann.
Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept.
J Am Acad Dermatol, 46 (2002), pp. 113-115
[30.]
M.J. Cañizares, D.I. Smith, M.S. Conners, K.J. Maverick, M.P. Heffernan.
Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients.
Arch Dermatol, 142 (2006), pp. 1457-1461
[31.]
S. Prey, P.Y. Robert, M. Drouet, A. Sparsa, C. Roux, J.M. Bonnetblanc, et al.
Treatment of ocular cicatricial pemphigoid with the tumour necrosis alpha antagonist etanercept.
Acta Derm Venereol, 87 (2007), pp. 74-75
[32.]
P.S. Yamauchi, N.J. Lowe, V. Gindi.
Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept.
J Am Acad Dermatol, 54 (2006), pp. S121-S122
[33.]
B. Berookhim, H.D. Fischer, J.M. Weinberg.
Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept.
Cutis, 74 (2004), pp. 245-247
[34.]
E. Gubinelli, F. Bergamo, B. Didona, G. Annessi, F. Atzori, D. Raskovic.
Pemphigus foliaceus treated with etanercept.
J Am Acad Dermatol, 55 (2006), pp. 1107-1108
[35.]
M.W. Ziegenhagen, U.K. Benner, G. Zissel, P. Zabel, M. Schlaak, J. Muller-Quernheim.
Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers.
Am J Respr Crit Care Med, 156 (1997), pp. 1586-1592
[36.]
L. Armstrong, N.M. Foley, A.B. Millar.
Inter-relationship between tumour necrosis factor-alpha (TNF-alpha) and TNF soluble receptors in pulmonary sarcoidosis.
Thorax, 54 (1999), pp. 524-530
[37.]
J. Shupack, K. Siu.
Resolving granuloma annulare with etanercept.
Arch Dermatol, 142 (2006), pp. 394-395
[38.]
A. Kreuter, P. Altmeyer, T. Gambichler.
Failure of etanercept therapy in disseminated granuloma annulare.
Arch Dermatol, 142 (2006), pp. 1236-1237
[39.]
D.L. Cummins, K.M. Hiatt, D. Mimouni, C.A. Vander Kolk, B.A. Cohen, C.H. Nousari.
Generalized necrobiosis lipoidica trested with a combination of split-thickness autografting and immunomodulatory therapy.
Int J Dermatol, 43 (2004), pp. 852-854
[40.]
J.A. Zeichner, D.W. Stern, M. Lebwohl.
Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept.
J Am Acad Dermatol, 54 (2006), pp. S120-S121
[41.]
M. Feldman, C.D. Pusey.
Is there a role for TNF-α in antineutrophil cytoplasmic antibody-associated vasculitis? Lessons for other chronic inflammatory diseases.
J Am Soc Nephrol, 17 (2006), pp. 1243-1252
[42.]
Wegener's granulomatosis etanercept trial (WGET) Research Group.
Etanercept plus standard therapy for Wegener's granulomatosis.
N Engl J Med, 352 (2005), pp. 351-361
[43.]
R. Solans Laqué, J.A. Bosch Gil.
Fármacos antifactor necrosis tumoral en las vasculitis sistémicas.
Med Clin (Barc), 130 (2008), pp. 93-94
[44.]
E. Holler, H.J. Kolb, A. Moller, J. Kempeni, S. Liesenfeld, H. Pechumer, et al.
Increased serum levels of tumor necrosis factor alpha precede major complicactions of bone marrow transplantation.
Blood, 75 (1990), pp. 1011-1016
[45.]
V. Barak, F. Levi-Schaffer, B. Nisman, A. Nagler.
Cytokine dysregulation in chronic graft verus host disease.
Leuk Lymphoma, 17 (1995), pp. 169-173
[46.]
D. Wolff, V. Roessler, B. Steiner, S. Wilhelm, V. Weirich, J. Brenmoehl, et al.
Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
Bone Marrow Transplant, 35 (2005), pp. 1003-1010
[47.]
A. Sommer, P. Altmeyer, A. Kreuter.
A case of mucocutaneous Behçet's disease responding to etanercept.
J Am Acad Dermatol, 52 (2005), pp. 717-719
[48.]
M.A. Scheinberg.
Treatment of recurrent oral aphthous ulcers with etanercept.
Clin Exp Rheumatol, 20 (2002), pp. 733-734
[49.]
B.T. Kovach, K.T. Calamia, J.S. Walsh, W.W. Ginsburg.
Treatment of multicentric reticulohistiocytosis with etanercept.
Arch Dermatol, 140 (2004), pp. 919-921
[50.]
K. Lovelace, A. Loyd, D. Adelson, N. Crowson, J.R. Taylor, R. Cornelison.
Etanercept and the treatment of multicentric reticulohistiocytosis.
Arch Dermatol, 141 (2005), pp. 1167-1168
[51.]
P. Paquet, F. Paquet, W. Al Saleh, P. Reper, A. Vanderkelen, G.E. Pierard.
Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis.
Am J Dermatopathol, 22 (2000), pp. 413-417
Copyright © 2010. Academia Española de Dermatología y Venereología
